Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000037

Chief Operating Officer sold 5,000 shares at an average $63.88 ($319,384)

  • Chief Operating Officer acquired 5,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Sandler Laura Lee · Chief Operating Officer

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-05-01 Exercise or conversion : show line 1 in the form 10b5-1 +5,000 $7.80 $39,000 241,984 D
2026-05-01 Sale : show line 2 in the form 10b5-1 −2,200 $62.58 $137,685 239,784 D
2026-05-01 Sale : show line 3 in the form 10b5-1 −1,800 $64.15 $115,468 237,984 D
2026-05-01 Sale : show line 4 in the form 10b5-1 −300 $65.10 $19,530 237,684 D
2026-05-01 Sale : show line 5 in the form 10b5-1 −400 $66.06 $26,422 237,284 D
2026-05-01 Sale : show line 6 in the form 10b5-1 −200 $67.16 $13,431 237,084 D
2026-05-01 Sale : show line 7 in the form 10b5-1 −100 $68.48 $6,848 236,984 D
Open-market sales · 5,000 sh · avg $63.88 · $319,384

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-05-01 Exercise or conversion : show line 8 in the form 10b5-1 Employee Warrant (right to buy) −5,000 84,996 D
Loading xslF345X06/form4.xml…